Identification of genes that mediate sensitivity to cisplatin

Molecular Pharmacology

Volumn 60, Issue 6, 2001, Pages 1153-1160

  Niedner, H ^a   Christen, R ^a   Lin, X ^a   Kondo, A ^a   Howell, S B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CYTOTOXICITY; DICTYOSTELIUM DISCOIDEUM; DRUG DNA INTERACTION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR;

DICTYOSTELIUM DISCOIDEUM;

EID: 0035206720     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.60.6.1153     Document Type: Short Survey

References (87)

1. Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance
2. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma
3. CaaX converting enzymes
4. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
5. Spontaneous development of drug resistance: Mismatch repair and p53 defects in resistance to cisplatin in human tumor cells
6. Ixrl, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin
7. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
8. A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin
9. The Friedreich's ataxia gene encodes a novel phosphatidylinositol-4-phosphate 5-kinase
10. Specificity of platinum-DNA adduct repair
11. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair
12. How cells recognize damaged DNA: Clues from xeroderma pigmentosum and yeast
13. Advances in signalling by extracellular nucleotides, the role and transduction mechanisms of P2Y receptors
14. Cisplatin resistance and DNA repair
15. Characterization of a cAMP-dependent protein kinase mutant resistant to cisplatin
16. Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells
17. Cisplatin resistance and oncogenes-a review
18. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA
19. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma
20. Reversal of radiation-induced cisplatin resistance in murine fibrosarcoma cells by selective modulation of the cyclic GMP-dependent transduction pathway
21. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
22. The role of DNA mismatch repair in drug resistance
23. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells
24. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
25. Apoptosis in cancer therapy: Crossing the threshold
26. A novel role for DNA photolyase: Binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae
27. Genomic approaches to drug discovery
28. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents
29. Identification of p53 genetic suppressor elements which confer resistance to cisplatin
30. Transcription factor AP-2 activity is modulated by protein kinase A- mediated phosphorylation
31. Skittles, a Drosophila phosphatidylinositol 4-phosphate 5-kinase, is required for cell viability, germline development and bristle morphology, but not for neurotransmitter release
32. The budding yeast cohesin gene SCC1/MCD1/RHC21 genetically interacts with PKA, CDK and APC
33. Effect of cisplatin-based chemotherapy on emergence of cisplatin resistance, and its correlation with intracellular glutathione levels and accumulation of p53 protein in human ovarian cancer
34. Participation of p53 protein in the cellular response to DNA damage
35. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance
36. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
37. Involvement of the DNA mismatch repair system in antineoplastic drug resistance
38. The ORD1 gene encodes a transcription factor involved in oxygen regulation and is identical to IXR1, a gene that confers cisplatin sensitivity to Saccharomyces cerevisiae
39. Molecular basis for resistance to the anticancer drug cisplatin in Dictyostelium
40. The role of mismatch repair in DNA damage-induced apoptosis
41. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin
42. The role of DNA mismatch repair in cisplatin mutagenicity
43. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide
44. Cisplatin resistance and regulation of DNA repair in cAMP-dependent protein kinase mutants
45. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells
46. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand crosslinks in human gallbladder adenocarcinoma cells
47. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo
48. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
49. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
50. New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy
51. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems
52. Trophic actions of extracellular ATP: Gene expression profiling by DNA array analysis
53. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
54. Nucleotide receptors
55. Emergence of resistance to VP-16/cisplatin chemotherapy: Study in a lymphoblast model system
56. The other function of DNA photolyase: Stimulation of excision repair of chemical damage to DNA
57. The anaphase-promoting complex: New subunits and regulators
58. Cellular and molecular determinants of cisplatin resistance
59. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line
60. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units
61. Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: A novel mechanism of regulated trafficking
62. Sphingosine 1-phosphate signalling in mammalian cells
63. Bcl-2 and the regulation of programmed cell death
64. Cell signaling switches HOX-PBX complexes from repressors to activators of transcription mediated by histone deacetylases and histone acetyltransferases
65. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy
66. No "End of History" for photalyases
67. Lack of c-Jun activity increases survival to cisplatin
68. Cloning and characterization of the high-affinity cAMP phosphodiesterase of Saccharomyces cerevisiae
69. Overexpression of DNA replication and repair enzymes in cisplatin- resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine
70. A gene expression database for the molecular pharmacology of cancer
71. Expression of the yeast PHR1 gene is induced by DNA-damaging agents
72. Transport of cisplatin and bis-acetatoammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: Identification of a plasma membrane protein associated with cisplatin resistance
73. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake
74. Similarity among the Drosophila (6-4)photolyase, a human photolyase homolog, and the DNA photolyase-blue-light photoreceptor family
75. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts
76. Functional analysis of the yeast genome by precise deletion and parallel phenotypic characterization
77. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis
78. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis
79. Novel PI(4)P 5-kinase homologue, Fab1p, essential for normal vacuole function and morphology in yeast
80. Differential transactivation of human metallothionein-IIa in cisplatin- resistant and -sensitive cells
81. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines
82. A new class of DNA photolyases present in various organisms including aplacental mammals
83. Constitutive levels of cAMP-dependent protein kinase activity determine sensitivity of human multidrug-resistant leukaemic cell lines to growth inhibition and apoptosis by forskolin and tumour necrosis factor alpha
84. Role for lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damage
85. Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene
86. Cisplatin and DNA repair in cancer chemotherapy
87. Repair of cisplatin DNA adducts by the mammalian excision nuclease